^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    rapcabtagene autoleucel (YTB323)

    i
    Other names: YTB323, YTB-323, YTB 323
    Associations

    News

    Trials
    Company:
    Novartis
    Drug class:
    CD19-targeted CAR-T immunotherapy
    Related drugs:
    Associations

    News

    Trials
    17d
    A Study to Assess Safety, Cellular Kinetics and Exploratory Efficacy of Rapcabtagene Autoleucel in Rheumatoid Arthritis and Sjogren's Disease (clinicaltrials.gov)
    P1/2, N=27, Recruiting, Novartis Pharmaceuticals | N=18 --> 27
    Enrollment change
    |
    rapcabtagene autoleucel (YTB323)
    1m
    A Study of Rapcabtagene Autoleucel in Active, Refractory Systemic Lupus Erythematosus (SLE) Patients or Lupus Nephritis (LN) (AUTOGRAPH - SLE/LN) (clinicaltrials.gov)
    P2, N=179, Recruiting, Novartis Pharmaceuticals | Trial completion date: Jun 2033 --> Feb 2032 | Trial primary completion date: Jun 2029 --> Feb 2028
    Trial completion date • Trial primary completion date
    |
    rapcabtagene autoleucel (YTB323)
    4ms
    A Study to Assess Safety, Cellular Kinetics and Exploratory Efficacy of Rapcabtagene Autoleucel in Rheumatoid Arthritis and Sjogren's Disease (clinicaltrials.gov)
    P1/2, N=18, Recruiting, Novartis Pharmaceuticals | Trial primary completion date: Jun 2028 --> Sep 2028
    Trial primary completion date
    |
    rapcabtagene autoleucel (YTB323)
    5ms
    A Study to Assess Safety, Cellular Kinetics and Exploratory Efficacy of Rapcabtagene Autoleucel in Rheumatoid Arthritis and Sjogren's Disease (clinicaltrials.gov)
    P1/2, N=18, Recruiting, Novartis Pharmaceuticals
    New P1/2 trial
    |
    rapcabtagene autoleucel (YTB323)
    6ms
    CYTB323A12101: Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL (clinicaltrials.gov)
    P1/2, N=199, Active, not recruiting, Novartis Pharmaceuticals | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
    |
    CD19 positive
    |
    Imbruvica (ibrutinib) • rapcabtagene autoleucel (YTB323)
    6ms
    A Study of Rapcabtagene Autoleucel in Systemic Lupus Erythematosus (SLE) Patients With Active, Refractory Lupus Nephritis (LN) (clinicaltrials.gov)
    P2, N=144, Recruiting, Novartis Pharmaceuticals | Trial completion date: Jun 2030 --> Jun 2033
    Trial completion date
    |
    rapcabtagene autoleucel (YTB323)
    7ms
    Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Diffuse Cutaneous Systemic Sclerosis (clinicaltrials.gov)
    P2, N=86, Recruiting, Novartis Pharmaceuticals | Trial completion date: Dec 2030 --> Oct 2032
    Trial completion date
    |
    Rituxan (rituximab) • rapcabtagene autoleucel (YTB323)
    7ms
    An Open-label Study to Assess the Safety, Efficacy, and Cellular Kinetics of YTB323 in Relapsing Multiple Sclerosis (clinicaltrials.gov)
    P1/2, N=28, Recruiting, Novartis Pharmaceuticals | Trial completion date: Dec 2030 --> Oct 2030 | Trial primary completion date: Dec 2030 --> Oct 2030
    Trial completion date • Trial primary completion date
    |
    rapcabtagene autoleucel (YTB323)
    8ms
    Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Severe Active GPA or MPA (clinicaltrials.gov)
    P2, N=126, Recruiting, Novartis Pharmaceuticals | Not yet recruiting --> Recruiting
    Enrollment open
    |
    rapcabtagene autoleucel (YTB323)
    8ms
    An Open-label, Study to Assess Safety, Efficacy and Cellular Kinetics of YTB323 in Severe, Refractory Systemic Lupus Erythematosus (clinicaltrials.gov)
    P1/2, N=21, Active, not recruiting, Novartis Pharmaceuticals | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    rapcabtagene autoleucel (YTB323)
    9ms
    Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Severe Active GPA or MPA (clinicaltrials.gov)
    P2, N=126, Not yet recruiting, Novartis Pharmaceuticals
    New P2 trial
    |
    rapcabtagene autoleucel (YTB323)
    10ms
    Open-label, Multi-center, Phase I/II Study to Assess Safety, Disease Progression and Cellular Kinetics Following YTB323 Administration in Participants With Non-active Progressive Multiple Sclerosis (PMS) (clinicaltrials.gov)
    P1/2, N=28, Recruiting, Novartis Pharmaceuticals | Not yet recruiting --> Recruiting
    Enrollment open
    |
    rapcabtagene autoleucel (YTB323)